SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Non-Tech : Franklin, Andrews, Kramer & Edelstein -- Ignore unavailable to you. Want to Upgrade?


To: scion who wrote (12533)2/3/2021 9:19:05 AM
From: scion1 Recommendation

Recommended By
MorningLightMountain

  Respond to of 12881
 
So you got the vaccine. Can you still infect people? Pfizer is trying to find out.

For now, even if you’ve had covid-19 or been given the shot, it's smart to keep your mask on.

by Antonio Regaladoa
February 2, 2021
technologyreview.com

Sebastián De Toma joined Pfizer’s clinical trial last year, getting his shots in August and September. The Argentinian journalist still doesn’t know if he got the real covid-19 vaccine or the placebo, but on Sunday, January 31, the trial doctors called him with a new offer.

Would De Toma be willing to undergo a series of nasal swabs to regularly test for the virus? He says the doctors offered to send Cabify (a Spanish ride-sharing service) to bring him to the Hospital Militar in Buenos Aires. “They’ll swab me on the go, through the car window, and that’s it,” says De Toma.

The extra coronavirus tests, being offered to some volunteers in Argentina and in the US, are part of a plan by Pfizer to help answer a key covid unknown—how often vaccinated people develop asymptomatic coronavirus infections and whether they can still spread the virus, despite getting the shot.

Whether or not the vaccines stop “onward transmission” of the virus is likely to be a critical variable in determining how the pandemic plays out and how soon life goes back to normal. Right now, researchers say, their best guess is that vaccines will reduce transmission but may not prevent it entirely.

“We don’t know, but it’s an important question because the answer will influence mask wearing; it will influence behavior; it relates to comfort going to restaurants and movies and the overall benefit we can expect with vaccines,” says Lawrence Corey, who leads operations for the Covid-19 Prevention Network, which carried out several US vaccine trials.


The silent spreader mystery

“There are three things a vaccine can do: stop you from acquiring the disease altogether, stop onward transmission, and stop symptoms,” says Jeffrey Shaman, a public health researcher at Columbia University. A perfect vaccine would create what is called “sterilizing” immunity, which means the virus can’t get a foothold in your body at all. Some inoculations, however, do allow low-level infections that people's immune systems fight off without any symptoms. Their bodies still accumulate a certain quantity of the virus, which they may be able to transmit to others.

The reason we don’t know how well vaccines stop this transmission is that it’s expensive and complicated to measure. When companies like Pfizer, Novavax, Moderna Therapeutics, and others launched big studies of their new covid-19 vaccines last year, they were testing whether the vaccines could prevent people who caught the disease from getting sick or dying. The results on that count were impressive: hardly anyone who is vaccinated ends up in an ICU on a respirator.

What they didn’t measure was the “indirect” effect of vaccines in preventing the further spread of the virus, even though some computer models have predicted that blocking transmission could save more lives. One model, published in August by a team at Emory University, found that a vaccine that’s good at stopping spread, but not very good at stopping disease, would still lead to fewer deaths overall because it would slow the outbreak enough to reduce the total number of people who get infected.

A step toward understanding how often vaccinated people spread the virus is what Pfizer is doing now: trying to figure out whether people like De Toma are getting infected without ever feeling sick.

The evidence so far suggests that vaccines should cut the chance of transmission, but may not eliminate it. For example, vaccinated monkeys spritzed with the virus do get infected but don’t become particularly sick. Overall, they have much less virus in their airways. “There is strong evidence that contagiousness is correlated with symptoms. If you can cut down symptoms, you are probably cutting down transmission,” says Shaman.

But that doesn’t mean there is no spread. Early in the pandemic, researchers discovered that some people who caught the coronavirus and never felt sick were still spreading the disease. The evidence now suggests that the role of such “silent spreaders” is substantial, even though they tend to infect fewer people on average. In a report published January 7, a team including epidemiologists at the Centers for Disease Control and Prevention estimated that a third of people infected with the coronavirus never develop symptoms and that they cause about a quarter of all spread.


Moderna Therapeutics, maker of another vaccine, did not reply to questions about whether it is studying transmission. However, preliminary data the company submitted to the US Food and Drug Administration in December offered one clue: people who got one dose of the vaccine were 66% less likely to turn up positive on a coronavirus test than those who got the placebo. Moderna suggested that “that some asymptomatic infections start to be prevented after the first dose.”

While looking for the virus in people’s noses can detect silent infections, it doesn’t actually prove whether these people can then infect others. To figure that out, researchers at the Covid-19 Prevention Network last year proposed studying more than 20,000 students on two dozen US campuses, including Louisiana State University. They proposed “almost daily” nose swabs to monitor exactly when the virus appeared, and in what amounts, in the airways of both vaccinated and unvaccinated students. Then, with contact tracing, they hoped to map how often vaccinated students spread the virus.

“You can learn a lot by understanding the acquisition and viral titers in the nose,” says Corey. “Then close contact tracing could estimate how often the people spread the virus, which is known as forward transmission.”

On December 31, the Wall Street Journal reported that the proposed study had failed to win funding, because of high costs and questions over its feasibility. Corey says the group has since updated the proposal and that it again being considered by the National Institutes of Health. He believes the study is worth the effort. “We just need to know,” he says. “Because we may need to turn our attention to the kinds of vaccines that do reduce transmission.”

Stemming the flood


Researchers know that stopping transmission is the only way to get rid of the coronavirus for good. One way the pandemic can end is via “herd immunity”—that is, when enough people are vaccinated, or infected, for the outbreak to recede on its own because there aren’t enough people left to infect. That threshold is commonly thought to be about 70% of the population.

But if vaccinated people are “leaky”—if they can still spread the virus sometimes—the threshold will rise. In fact, according to basic outbreak math, if the vaccine stops anything less than two-thirds of transmission events, it’s impossible to reach herd immunity at all. And that’s not even considering that many people will refuse the vaccine, nor mounting evidence that immunity may not last against new variants of the virus.

So if the vaccines don’t almost completely stop transmission, “you will still have continued circulation and there won’t be much herd immunity,” Corey says. “It’s going to be in the population a long time.”


Jody Lanard, a medical risk communicator who has worked with the World Health Organization, says until questions about vaccine transmission are answered, public health officials will likely send out contradictory messages. On the one hand, she says, exhorting people to “keep wearing a mask” implies that a vaccinated person can still transmit the virus. At the same time, encouraging everyone to get vaccinated, even those who are not in a high-risk group, “leans heavily on the notion that transmission will likely be reduced by vaccination.”

Lanard herself took extreme measures to avoid the virus, barely venturing out; when she did, she wore special masks and goggles in her building’s elevator. She says she recently managed to get a vaccine appointment, and now that she’s had the shot, she thinks she may loosen up and visit with some younger relatives.

But Lanard says she is still going to wear a mask at least until case numbers in New York, where she lives, go back down. “It would be so stupid to catch covid at this point in the pandemic,” she says. “I’m a fairly well-protected grandmom now, thanks to the vaccine. The last thing I want to do is infect some unprotected grandmom.”


technologyreview.com



To: scion who wrote (12533)2/4/2021 5:08:14 AM
From: scion1 Recommendation

Recommended By
MorningLightMountain

  Read Replies (2) | Respond to of 12881
 
About 4,000 Covid variants across world, says UK minister

Nadhim Zahawi says Britain is storing mutations so it is better prepared to update vaccines


Sarah Marsh @sloumarsh
Thu 4 Feb 2021 04.33 ESTLast modified on Thu 4 Feb 2021 04.37 EST
theguardian.com

There are roughly 4,000 variants of Covid-19 around the world, according to the UK vaccines minister, who said the British government was storing the mutations so it was better prepared to update vaccines as needed.

Nadhim Zahawi told Sky News there was a “library” of coronavirus mutations being stored to make sure the UK could respond appropriately.

Concerning variants have been identified in California, South Africa and Brazil, as well as the UK. Zahawi said: “There are about 4,000 variants around the world of Covid now.


“We have the largest genome sequencing industry – we have about 50% of the world’s genome sequencing industry – and we are keeping a library of all the variants so that we are ready to be able to respond, whether in the autumn or beyond, to any challenge the virus may present, and produce the next vaccine so we can always protect the United Kingdom and of course the rest of the world as well.”

He said manufacturers including Pfizer/BioNTech, Moderna and Oxford/AstraZeneca were looking at how they could improve their vaccines to be ready for any variant.


In a separate interview with BBC Breakfast, Zahawi said infection transmission studies among vaccinated care home residents and frontline healthcare workers would provide more information on a roadmap for reopening the economy.

“The phase 1, the top nine [groups], is 99% of mortality so I think we should be by then having really good robust data. We’ve got two sets of data we’re waiting for,” he said.

“One is in care homes where Public Health England are testing residents because they are in category one, and one with health frontline workers who are category two of that top nine.

“Those pieces of evidence, coupled with other pieces of evidence from other countries as well, will hopefully give us a very clear roadmap to opening the economy where we see a huge reduction, hopefully, in deaths and hospitalisation.”

When pushed on when the first nine groups in the priority list would have received their vaccine, he said people could “do the maths”.

He told BBC Breakfast: “We will set out our target (for vaccinating groups 5-9) after we have hit our February 15 target. But you can do the maths. We did 600,000 in a single day – the deployment infrastructure that we’ve built can do as many vaccines as we get supply, so the limiting factor will be vaccine supply.

“You can see that in the next 10 or so days, we’ve got to do another almost touching 5 million and so if we keep that rate up we will very quickly go down the list of the top nine.”

Asked whether that meant it would take another 35 days from 15 February to have jabbed all 31 million people in the first nine cohorts, Zahawi replied: “That assumes the supply, so I don’t want to commit to a date without going through it with a very fine-tooth comb with the whole team, because our limiting factor is the supply of vaccines ultimately.

“With any manufacturing process, especially one that is new, there are challenges around that, as we’ve seen in Europe and as we saw in the early days in the UK as well.”

theguardian.com